Reduce time to develop and validate your oncology liquid biopsy research and diagnostic assay development by utilizing our TSO500 ctDNA application to detect ctDNA genomic variants and biomarker signatures
HudsonAlpha Discovery’s TSO500 ctDNA NGS service provides high sensitivity detection of genomic variants across 523 DNA genes in various cancer indications from liquid biopsy plasma samples, including microsatellite instability (MSI) and tumor mutational burden (TMB) immuno-oncology biomarkers.
For Research Use Only.
An On Demand Webinar
High Sensitivity TSO500 Detection of Somatic Variants in Matched FFPE and Plasma: Implications for Liquid Biopsy Biomarker Evaluations
Presented by Shawn Levy, PhD (Discovery Life Sciences)
Watch this webinar to learn how Discovery leverages TSO500 sequencing capabilities to conduct a comparative analysis of paired plasma and FFPE samples, and more.
Our TSO500 NGS services provide pan-cancer genomic biomarker analysis to enable:
Discovery and verification of the presence of genomic biomarker targets and signatures in liquid biopsy ctDNA
Retrospective identification of potential oncology clinical trial patient responders versus non-responders based on genomic profiles
RUO development and orthogonal validation of novel liquid biopsy diagnostic solutions
Combine the matching TSO500 ctDNA and TSO500 Solid Tumor applications to develop and validate non-invasive liquid biopsy assays from matched-patient Plasma and FFPE samples
Service Performance Data
Using commercially available reference standards in our optimized and automated nucleic acid extraction, library construction, and sequencing workflows, we demonstrate the accuracy, sensitivity, reproducibility, and concordance of our matched liquid biopsy ctDNA – solid tumor TSO500 NGS assay service.
Limit of Detection:
>1% Allele Fractions
ctDNA / Solid Tumor Concordance:
Technical Data Sheet
Download our Technical Data sheet to learn more about service performance data.